Immuron Appoints Gary S. Jacob, Ph.D., Experienced US Based Biotechnology Executive, as CEO
19 nov. 2018 09h00 HE
|
Immuron Limited
MELBOURNE, Australia, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Immuron Limited, (IMC or the Company), (ASX: IMC; NASDAQ: IMRN), is pleased to announce the appointment of Gary S. Jacob as Chief Executive...
NASH clinical trial presentation and continued revenue growth
09 nov. 2018 06h00 HE
|
Immuron Limited
Key Highlights: Professor Arun Sanyal to present IMM-124E NASH clinical trial results at the Liver Meeting in San FranciscoTravelan® on display at HealthEdAustralian Travelan® sales continue to...
US Department of Defense Reports Travelan Protects Against Shigella in Primates
05 sept. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Travelan® pre-clinical shigellosis challenge studies in non-human primates (NHP) successfully completedTravelan® prevented clinical shigellosis (bacillary dysentery) in 75% of...
Immuron Reports Record Revenue Exceeding AU$2 million for the FY18 year
25 juil. 2018 10h00 HE
|
Immuron Limited
Key Highlights: Global Immuron Ltd sales revenue reached an AU$2million milestone continuing its upward trend and enjoying a 29% sales increase compared to FY17.US Travelan® sales continue to exceed...
Immuron Announces it has Received a European Patent Grant for NASH treatment
24 juil. 2018 06h30 HE
|
Immuron Limited
MELBOURNE, Australia, July 24, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN) is an Australian microbiome biopharmaceutical Company focused on developing and commercializing orally...
US Department of Defense Research Collaboration Moves Forward
24 juil. 2018 06h28 HE
|
Immuron Limited
Key Highlights: Three US Defense Health funded research projects on Travelan® successfully completedStudies commissioned by the US Department of Defense to evaluate Travelan®’s ability to...
Immuron Announces Board Appointment
25 juin 2018 20h36 HE
|
Immuron Limited
MELBOURNE, Australia, June 25, 2018 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company Immuron Limited (ASX:IMC), is pleased to announce the appointment of New York based Mr. Richard Jay...
Immuron CEO to Present at RedChip Global Online Growth Conference
23 avr. 2018 18h57 HE
|
Immuron Limited
MELBOURNE, Australia, April 23, 2018 (GLOBE NEWSWIRE) -- Immuron Limited (ASX:IMC) (NASDAQ:IMRN), Australian microbiome biopharmaceutical company focused on developing and commercialising orally...
Immuron’s Travelan® Sales Continue to Soar in Third Quarter of FY2018 in Australian & US Markets
23 avr. 2018 09h30 HE
|
Immuron Limited
Key Highlights: US Travelan® sales continue an upward trend with a 95% increase in the Third Quarter of 2018 compared to the same period last year. YTD US sales (End March 2018) climbed to...
Immuron Announces A$5.1M Private Placement to U.S. Fund
13 mars 2018 18h20 HE
|
Immuron Limited
MELBOURNE, Australia, March 13, 2018 (GLOBE NEWSWIRE) --
Immuron Limited (ASX:IMC) (NASDAQ:IMRN), an Australian microbiome biopharmaceutical company focused on developing and...